Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website http://www.gastrores.org

Original Article

Volume 2, Number 6, December 2009, pages 311-316


No Association of Obesity and Type 2 Diabetes Mellitus Related Genetic Variants With Colon Cancer

Tables

Table 1. Descriptive Characteristics of Kentucky Colon Cancer Study Population
 
Cases (N = 561)Controls (N = 721)p*
*Univariate (t-test or chi-square) p-value for association with colon cancer. For family history, type 2 diabetes diagnosis and NSAID use, this is a test of difference in positive vs. negative responses between cases and controls, ignoring unknown or missing data. **Self-reported physician diagnosis of type 2 diabetes Regular non-steroidal anti-inflammatory drug (NSAID) use was defined as reporting ever use of NSAIDs at least twice a week for at least six months. ‡Family history of colorectal cancer.
Gender – N (%)< 0.001
  Male266 (47.3)274 (38.0)
  Female295 (52.7)447 (61.0)
Mean (stddev) age62.8 (10.7)58.3 (10.9)< 0.001
Race – N (%)0.24
  African-American27 (4.8)23 (3.2)
  Caucasian526 (93.8)678 (94.0)
  Other8 (1.4)15 (2.1)
  Unknown0 (0)5 (0.7)
Body Mass Index (kg/m2)29.3 (6.1)28.3 (6.2)0.0077
Diabetes Diagnosis (%)**0.019
  Yes105 (18.7)105 (14.6)
  No397 (70.8)568 (78.8)
  Unknown59 (10.5)48 (6.7)
Family History‡0.0014
  Yes94 (16.8)72 (10.0)
  No297 (52.9)395 (54.8)
  Unknown170 (30.3)254 (35.2)
Regular NSAID Use0.16
  Yes235 (41.9)306 (42.4)
  No131 (23.4)138 (19.1)
  Unknown195 (38.8)277 (38.4)
HHEX – rs11118750.13
  CC217 (38.7)241 (33.4)
  CT255 (45.5)348 (48.3)
  TT88 (15.7)131 (18.2)
  No call1 (0.2)1 (0.1)
KCNJ11-rs52190.39
  CC226 (40.3)304 (42.2)
  CT265 (47.2)316 (43.8)
  TT68 (12.1)100 (13.9)
  No call2 (0.4)1 (0.1)
rs93000390.73
  AA9 (1.6)8 (1.1)
  AC103 (18.4)136 (18.9)
  CC448 (79.9)576 (79.9)
  No call1 (0.2)1 (0.1)
SLC30A8 – rs13266340.48
  CC274 (48.9)329 (45.6)
  CT230 (41.0)319 (44.2)
  TT55 (9.8)71 (9.9)
  No call2 (0.4)2 (0.3)
FTO-rs9939609
  AA
0.66
  AA90 (16.0)121 (16.8)
  AT252 (44.9)336 (46.6)
  TT217 (38.7)261 (36.2)
  No call2 (0.4)3 (0.4)
FTO-rs80501360.74
  AA91 (16.2)119 (16.5)
  AC250 (44.6)336 (46.6)
  CC217 (38.7)265 (36.8)
  No call3 (0.5)1 (0.1)
CDKN2 – rs108116610.34
  CC21 (3.7)19 (2.6)
  CT142 (25.3)202 (28.0)
  TT395 (70.4)500 (69.4)
  No call3 (0.5)0 (0)
CDKAL1 – rs77548400.75
  GG241 (43.0)325 (45.1)
  CG254 (45.3)313 (43.4)
  CC64 (11.4)81 (11.2)
  No call2 (0.4)2 (0.3)
TCF2 – rs44307960.81
  AA141 (25.1)178 (24.7)
  AG297 (52.9)374 (51.9)
  GG122 (21.7)168 (23.3)
  No call1 (0.2)1 (0.1)

 

Table 2. Descriptive Characteristics of Kentucky Colon Cancer Study Population
 
GeneSNPBase Model*Full Model†
Case/ControlORp‡ORp‡
*Logistic regression controlling for age, sex and race (558 cases and 698 controls). †Logistic regression controlling for age, sex, race, family history of colorectal cancer, non-steroidal anti-inflammatory. drug (NSAID) use and body mass index (BMI) (503 cases and 670 controls with complete data). ‡p-value of additive, dominant or recessive genetic model.
HHEXrs1111875
  CC217/2411.0 (ref)0.201.0 (ref)0.22
  CT255/3480.80 (0.62 - 1.03)0.79 (0.60 - 1.03)
  TT88/1310.85 (0.60 - 1.19)0.87 (0.61- 1.24)
TT vs. CC/CT0.97 (0.52 - 3.10)0.841.00 (0.72 - 1.37)0.98
CT/TT vs. CC0.81 (0.64 - 1.03)0.0890.81 (0.63 - 1.04)0.097
KCNJ11rs5219
  CC226/3041.0 (ref)0.931.0 (ref)0.32
  CT265/3161.15 (0.90 - 1.47)1.20 (0.92 - 1.56)
  TT68/1000.92 (0.63 - 1.32)0.98 (0.67 - 1.56)
TT vs. CC/CT0.85 (0.60 - 1.20)0.350.89 (0.62 - 1.27)0.89
CT/TT vs. CC1.10 (0.87 - 1.39)0.441.15 (0.90 - 1.47)0.28
rs9300039
  CC448/5761.0 (ref)0.641.0 (ref)0.85
  AC103/1361.04 (0.78 - 1.41)1.03 (0.75 - 1.41)
  AA9/81.28 (0.48 - 3.45)1.35 (0.46 - 3.95)
AA vs. CC/CA1.28 (0.47 - 3.47)0.631.35 (0.46 - 3.92)0.59
AC/AA vs. CC1.06 (0.79 - 1.41)0.711.05 (0.77 - 1.42)0.77
SLC30A8rs13266634
  CC274/3291.0 (ref)0.601.0 (ref)0.61
  CT230/3190.92 (0.72 - 1.18)0.88 (0.68 - 1.14)
  TT55/710.94 (0.63 - 1.41)0.99 (0.65 - 1.51)
TT vs. CC/CT0.98 (0.67 - 1.44)0.941.05 (0.70 - 1.57)0.81
CT/TT vs. CC0.93 (0.74 - 1.17)0.520.90 (0.71 - 1.15)0.40
FTOrs9939609
  TT217/2611.0 (ref)0.351.0 (ref)0.40
  AT252/3360.90 (0.69 - 1.15)0.84 (0.65 - 1.10)
  AA90/1210.86 (0.62 - 1.22)0.84 (0.58 - 1.19)
AA vs. TT/AT vs. AA0.88 (0.70 - 1.12)0.540.92 (0.66 - 1.27)0.61
AT/AA vs. TT0.92 (0.67 - 1.25)0.320.84 (0.65 - 1.08)0.17
FTOrs8050136
  CC217/2611.0 (ref)0.421.0 (ref)0.48
  AC250/3360.90 (0.70 - 1.16)0.85 (0.65 - 1.11)
  AA91/1190.89 (0.64 - 1.25)0.87 (0.61 - 1.11)
AA vs. CC/AC0.90 (0.71 - 1.14)0.720.86 (0.67 - 1.83)0.23
AC/AA vs. CC0.95 (0.70 - 1.29)0.370.95 (0.69 - 1.32)0.76
CDKN2rs10811661
  TT395/5001.0 (ref)0.931.0 (ref)0.086
  CT142/2020.88 (0.68 - 1.15)0.85 (0.65 - 1.12)
  CC21/191.59 (0.83 - 3.03)1.88 (0.93 - 3.81)
CC vs. TT/CT1.65 (0.86 - 3.16)0.131.97 (0.98 - 3.97)0.057
CT/CC vs. TT0.94 (0.73 - 1.21)0.630.93 (0.71-1.21)0.56
CDKAL1rs7754840
  GG241/3251.0 (ref)0.351.0 (ref)0.34
  CG254/3131.15 (0.90 - 1.47)1.21 (0.94 - 1.57)
  CC64/811.11 (0.76 - 1.61)1.16 (0.78 - 1.73)
CC vs. GG/CG1.04 (0.73 - 1.50)0.871.05 (0.72 - 1.53)0.80
CG/CC vs. GG1.14 (0.91 - 1.44)0.251.20 (0.94 - 1.53)0.15
TCF2rs4430796
  AA141/1781.0 (ref)0.391.0 (ref)0.74
  AG297/3740.94 (0.71 - 1.25)0.95 (0.71 - 1.28)
  GG122/1680.86 (0.62 - 1.20)0.87 (0.61 - 1.24)
GG vs. AA/AG0.90 (0.68 - 1.18)0.430.90 (0.67 - 1.20)0.48
AG/GG vs. AA0.92 (0.70 - 1.20)0.530.92 (0.70 - 1.23)0.60